Trastuzumab Rezetecan Application Scope

Indication: Unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating HER2 (ERBB2) mutations in adult patients who have received at least one prior systemic therapy.

Trastuzumab Rezetecan Characteristics

Ingredients: Trastuzumab rezetecan (HER2-directed antibody–drug conjugate).
Properties: HER2-targeting antibody conjugated to a cytotoxic payload; internalizes into HER2-expressing tumor cells and releases payload to kill tumor cells; designed to have activity in HER2-mutant and HER2-overexpressing tumors, including intracranial activity reported.
Packaging Specification: 0.1 g per vial.
Storage: Refrigerate at 2 °C–8 °C; protect from light; do not freeze
Expiry Date: See package label
Executive Standard: As per national drug standards (refer to label)
Approval Number: Available on the official package insert.
Date of Revision: See latest insert.
Manufacturer: Jiangsu Hengrui Medicine Co., Ltd.

Guidelines for the Use of Avida

Dosage and Administration:
- Recommended Dose: 4.8 mg/kg intravenous infusion every 3 weeks (or as directed by official label).
- Administration: Intravenous infusion; follow recommended infusion rate and dilution instructions.
- Missed Dose: Contact the physician to reschedule as soon as possible; do not double-dose.
Adverse Reactions:
- Common Adverse Reactions:
  - Nausea
  - fatigue
  - alopecia
  - neutropenia
  - anemia
  - thrombocytopenia
  - elevated liver enzymes
  - vomiting
- Serious Adverse Reactions:
  - Interstitial lung disease (ILD)/pneumonitis (can be severe),
  - febrile neutropeni
  - severe hepatic toxicity
Contraindications:
- Hypersensitivity to trastuzumab, rezetecan, or excipients.
- Contraindicated during pregnancy unless the benefits outweigh the risks.
Precautions:
- Confirm HER2 mutation status before starting treatment.
- Monitor for ILD/pneumonitis, CBC, and liver function during therapy.
- Consider cardiac monitoring due to HER2-targeted therapy–related cardiotoxicity.

Trastuzumab Rezetecan Interactions

No major CYP-mediated drug–drug interactions reported.
Use caution with other drugs that cause pulmonary or hepatic toxicity.
Safety of combination with other HER2-targeted agents not fully established—should follow clinical protocol.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.